Alan Brooks

Alan Brooks

Auto-generated profile, based on publicly available information

Alan Brooks

Affiliation Bridges to Development, Geneva, Switzerland

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2023 in Vaccine
Verified
Journal Article
Open access
ALAnn Lindstrand
Ann Lindstrand
EMEric Mast
Eric Mast
SCSarah Churchill
Sarah Churchill
NRNargis Rahimi
Nargis Rahimi
JGJan Grevendork
Jan Grevendork
KOKatherine L. O'Brien
Katherine L. O'Brien

11 July 2012 in Global Public Health
Verified
Journal Article
Open access
ABAlan Brooks
Alan Brooks
JNJulia K. Nunes
Julia K. Nunes
AGAndrew Garnett
Andrew Garnett
RBRobin Biellik
Robin Biellik
DLDidier Leboulleux
Didier Leboulleux
CLChristian Loucq
Christian Loucq
Many new interventions are being created to address health problems of the developing world. However, many developing countries have fragile health systems and find it difficult to accommodate change. Consequently, it is essential that new interventions are well aligned with health systems and their users. Establishing target product profiles (TPPs) is a critical, early step towards tailoring interventions to suit both of these constituencies. Specific analyses can help identify and establish relevant TPP criteria such as optimal formulation, presentation and packaging. Clinical trials for a new intervention should be designed to address both TPP-specific questions and anticipated use of the intervention in target countries. Examples are provided from research on malaria vaccines that are also applicable to other new public health interventions.

9 April 2021 in Cancer Research
Verified
Journal Article
Open access
PDF file
PTPoonam Tewary
Poonam Tewary
ABAlan D. Brooks
Alan D. Brooks
YXYa-Ming Xu
Ya-Ming Xu
EWE.M. Kithsiri Wijeratne
E.M. Kithsiri Wijeratne
ABAshley L. Babyak
Ashley L. Babyak
TSThomas J. Sayers
Thomas J. Sayers
Screening for sensitizers of cancer cells to TRAIL-mediated apoptosis identified a natural product of the 17β-hydroxywithanolide (17-BHW) class, physachenolide C (PCC), as a promising hit. In this study, we show that PCC was also able to sensitize melanoma and renal carcinoma cells to apoptosis in response not only to TRAIL, but also to the synthetic polynucleotide poly I:C, a viral mimetic and immune activator, by reducing levels of antiapoptotic proteins cFLIP and Livin. Both death receptor and TLR3 signaling elicited subsequent increased assembly of a proapoptotic ripoptosome signaling complex. Administration of a combination of PCC and poly I:C in human M14 melanoma xenograft and a syngeneic B16 melanoma model provided significant therapeutic benefit as compared with individual agents. In addition, PCC enhanced melanoma cell death in response to activated human T cells in vitro and in vivo in a death ligand–dependent manner. Biochemical mechanism-of-action studies established bromo and extraterminal domain (BET) proteins as major cellular targets of PCC. Thus, by targeting of BET proteins to reduce antiapoptotic proteins and enhance caspase-8–dependent apoptosis of cancer cells, PCC represents a unique agent that can potentially be used in combination with various immunotherapeutic approaches to promote tumor regression and improve outcome.Significance: These findings demonstrate that PCC selectively sensitizes cancer cells to immune-mediated cell death, potentially improving the efficacy of cancer immunotherapies.

31 December 2024 in PLOS Global Public Health
Verified
Journal Article
Open access
PDF file
ÍUÍsis Caroline Umbelino-Walker
Ísis Caroline Umbelino-Walker
ASAna Paula Szylovec
Ana Paula Szylovec
BDBrice Alain Dakam
Brice Alain Dakam
AMAsta Monglo
Asta Monglo
IJIan Jones
Ian Jones
ABAlan Brooks
Alan Brooks
The Immunization Agenda 2030 (IA2030) has been endorsed at the World Health Assembly as the world’s strategy for immunization. The Movement for IA2030 is a voluntary collective of immunization practitioners, principally from low- and middle-income countries, who have pledged to support each other to accelerate local action in support of this global strategy. Collective action is facilitated by the peer learning platform established by The Geneva Learning Foundation (TGLF). We reviewed existing data from Movement participants and collected additional survey data to explore two aspects of sustainability of the Movement: why immunization practitioners participate and how much time and resources they contribute. Quantitative analyses of an existing large data set (n = 5682 participants) were complemented by analyses of data collected through a new survey (n = 291) and focus groups of Movement participants. The most commonly cited reason for participating (32% of responses) was to share experience and learn from others. This was generally true across all levels of experience, gender and place of work, suggesting a common rationale among immunization practitioners in different settings. It was a particularly strong motivation for the most experienced practitioners and those working in a setting with a strong organizational learning culture. New survey data revealed a high degree of intrinsic personal motivation to participate, through commitment of significant time and financial resources, with 47% (n = 136) of respondents committing personal finances to implement an action plan. Focus group discussions provided insights into the implications of findings for sustaining the Movement. Collectively, the analyses highlight key aspects of voluntary collective action to achieve global immunization goals through local action, to inform efforts to ensure long-term sustainability of the Movement.

9 July 2026 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
IWIsrael Wuresah
Israel Wuresah
ABAlan Brooks
Alan Brooks
NKNikita Kubal
Nikita Kubal
MGMarina Gold
Marina Gold
AKAlejandro Krolewiecki
Alejandro Krolewiecki
JJJulie Jacobson
Julie Jacobson
Background: Medicine donation programs have been central to neglected tropical disease (NTD) control, particularly for soil-transmitted helminths (STH), but growing concerns about sustainability, supply continuity, and country ownership highlight the need for new access models. A novel fixed-dose combination (FDC) of ivermectin and albendazole, recently endorsed by the European Medicines Agency, offers programmatic advantages over monotherapy. Unlike some existing treatments, the FDC may not be donated. This paper examines how the current drug donation landscape for STH shapes the prospects for future supply and financing of the FDC. Methods: Evidence for this paper was synthesized from a structured review of peer-reviewed and gray literature, supplemented by expert consultation. Data drawn from WHO’s Service Availability and Readiness Assessment (SARA) database on essential medicine availability, estimates of public health spending, and the World Bank’s World Development Indicators on health expenditure support the qualitative reports from sampled sources. Findings were interpreted within a framework examining three interrelated determinants of sustainable access: facility-level availability of essential medicines, health financing patterns, and existing donation models. Results: The analysis involved the review of 35 sources on essential medicine availability, financing, and supply of critical medical products, and medicine donation. SARA data showed striking gaps in essential medicine availability in health facilities, with some low- and lower-middle-income countries (LICs, LMICS) reporting zero facilities with sustainable availability. On health financing, African and Asian countries are spending only about half of what is called for in targets. Low- and lower-middle income countries remain heavily dependent on external aid and out-of-pocket spending, in stark contrast to high- and upper-middle and high-income countries where domestic public financing predominates. Further, no pooled or coordinated global financing mechanism currently exists for NTD medicines, leaving supply fragmented and reliant on donations. Existing donation programs for albendazole, mebendazole, and ivermectin have achieved wide-scale coverage and impact but have not fostered sustainable domestic procurement or integration into primary health care systems. Conclusions: Introduction of the FDC in the absence of donation schemes poses significant financing and supply challenges, especially for LICs and LMICs where essential medicine availability is already limited. However, it also presents an opportunity to reset NTD access models by embedding sustainable financing strategies, such as pooled procurement, tiered pricing, and primary health care integration, from the outset. Early planning with manufacturers, donors, and governments will be essential to ensure equitable access and country ownership of this novel treatment.

27 December 2025 in International Journal of Health Policy and Management
Verified
Journal Article
Open access
NWNicola Watt
Nicola Watt
DYDiana Yousef
Diana Yousef
ABAlan Brooks
Alan Brooks
EJElizabeth Juma
Elizabeth Juma
KSKristin Saarlas
Kristin Saarlas
NENgozi A. Erondu
Ngozi A. Erondu